

LITERATURA

1. Preisser F, Chun KH, Banek S, et al. Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. *Prostate International* [Internet]. 2021;9(3):113-118 [cit. 2023-09-02]. Available from: doi:10.1016/j.prnil.2020.12.003.
2. Sutera P, Eecken van Der K, Kishan AU, et al. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. *Prostate Cancer and Prostatic Diseases* [Internet]. 2022;25(4):713-719 [cit. 2023-09-02]. Available from: doi:10.1038/s41391-021-00484-4.
3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians* [Internet]. 2021;71(3):209-249 [cit. 2023-09-02]. Available from: doi:10.3322/caac.21660.
4. Siegel DA, O'Neill ME, Richards TB, et al. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity – United States, 2001–2017. *MMWR. Morbidity and Mortality Weekly Report* [Internet]. 2020;10-16;69(41):1473-1480 [cit. 2023-09-03]. Available from: doi:10.15585/mmwr.mm6941a1.
5. Vale CL, Fisher DJ, Godolphin PJ, et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. *The Lancet Oncology* [Internet]. 2023;24(7):783-797 [cit. 2023-09-02]. Available from: doi:10.1016/S1470-2045(23)00230-9.
6. Francini E, Gray GP, Xie W, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). *The Prostate* [Internet]. 2018;78(12):889-895 [cit. 2023-09-02]. Available from: doi:10.1002/pros.23645.
7. Kyriakopoulos ChE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. *Journal of Clinical Oncology* [Internet]. 2018;04-10;36(11): 1080-1087 [cit. 2023-09-02]. Available from: doi:10.1200/JCO.2017.75.3657.
8. Fizazi K, Tran NP, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *New England Journal of Medicine* [Internet]. 2017;377(4): 352-360 [cit. 2023-09-02]. Available from: doi:10.1056/NEJMoa1704174.
9. James ND, Bono de JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. *New England Journal of Medicine* [Internet]. 2017;377(4):338-351. [cit. 2023-09-02]. Available from: doi:10.1056/NEJMoa1702900.
10. Modrá kniha České onkologické společnosti [Internet]. 29. Brno: Masarykův onkologický ústav; 2023 [cit. 2023-09-02]. Available from: <https://www.links.cz/lekar-a-multidisciplinari-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/>.
11. Astellas Pharma Europe B.V. Xtandi product information. 21. 6 2013. Available from: https://www.ema.europa.eu/en/documents/product-information/xtandi-epar-product-information_cs.pdf.
12. Wenzel M, Nocera L, Collà Ruvolo C, et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. *Prostate Cancer and Prostatic Diseases* [Internet]. 2022;25(2):139-148 [cit. 2023-09-05]. Available from: doi:10.1038/s41391-021-00395-4.
13. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *New England Journal of Medicine* [Internet]. 2019;07-04;381(1):13-24 [cit. 2023-09-02]. Available from: doi:10.1056/NEJMoa1903307.
14. Bayer AG. Nubeqa product information. 27. 3. 2020. Available from: <https://www.bayer.com/sites/default/files/Nubeqa%20-%2020SPC%20-%202027.2.2023.pdf>.
15. Sweeney Ch, Chen YH, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. *Journal of Clinical Oncology* [Internet]. 2014;06-20;32(18_suppl):LBA2-LBA2 [cit. 2023-09-02]. Available from: doi:10.1200/jco.2014.32.18_suppl.lba2.
16. Parker CE, Castro K, Fizazi A, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* [Internet]. 2020;31(9):1119-1134 [cit. 2023-09-02]. Available from: doi:10.1016/j.annonc.2020.06.011.
17. Feyerabend S, Saad F, Li T, et al. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. *European Journal of Cancer* [Internet]. 2018;103:78-87 [cit. 2023-09-02]. Available from: doi:10.1016/j.ejca.2018.08.010.
18. Parker ChC, James ND, Brawley ChD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. *The Lancet* [Internet]. 2018;392(10162):2353-2366 [cit. 2023-09-02]. Available from: doi:10.1016/S0140-6736(18)32486-3.
19. Mittal A, Sridhar SS, Ong M, et al. Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC) – A Potential New Standard of Care. *Current Oncology* [Internet]. 2023;30(4):4365-4378 [cit. 2023-09-02]. Available from: doi:10.3390/curroncol30040332.
20. Davis ID, Martin EJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. *New England Journal of Medicine* [Internet]. 2019;07-11;381(2):121-131 [cit. 2023-09-02]. Available from: doi:10.1056/NEJMoa1903835.
21. Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. *The Lancet* [Internet]. 2022;399(10336):1695-1707 [cit. 2023-09-02]. Available from: doi:10.1016/S0140-6736(22)00367-1.
22. Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. *New England Journal of Medicine* [Internet]. 2022;03-24;386(12):1132-1142 [cit. 2023-09-02]. Available from: doi:10.1056/NEJMoa2119115.
23. Sweeney ChJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. *The Lancet Oncology* [Internet]. 2023;24(4):323-334 [cit. 2023-09-02]. Available from: doi:10.1016/S1470-2045(23)00063-3.
24. Abdel-Aty H, James ND. The role of radiotherapy in oligometastatic hormone-sensitive prostate cancer. *Current Opinion in Urology* [Internet]. 2022;32(3):277-282 [cit. 2023-09-02]. Available from: doi:10.1097/MOU.0000000000000980.
25. Deek MP, Eecken van Der K, Sutera P, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. *Journal of Clinical Oncology* [Internet]. 2022;10-10;40(29):3377-3382 [cit. 2023-09-02]. Available from: doi:10.1200/JCO.22.00644.
26. Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. *JAMA Oncology* [Internet]. 2020;05-01;6(5) [cit. 2023-09-02]. Available from: doi:10.1001/jamaoncol.2020.0147.
27. Dai B, Zhang J, Wang H, et al. 618MO Local therapy to the primary tumour for newly diagnosed, oligo-metastatic prostate cancer: A prospective randomized, phase II, open-label trial. *Annals of Oncology* [Internet]. 2020;31 [cit. 2023-09-02]. Available from: doi:10.1016/j.annonc.2020.08.877.



NOVĚ: videokazuistiky



RWE a metastatický karcinom prostaty: kazuistika pacienta MUDr. Miroslav Hodek, Ph.D.



Enzalutamid v terapii pacienta s metastatickým hormonálně senzitivním karcinomem prostaty (mHSPC)


Kazuistické sdělení

Představení případu:

Pacient, 65 let, se dostavil v září 2022 s diagnózou metastatického karcinomu prostaty (mHSPC). Pacient byl předtím léčen abirateronem a prednisonem. Při posledním vyšetření (PSA 10,5 ng/ml) byl pacientovi doporučeno začít s léčbou enzalutamidem. Pacient byl informován o výhodách a rizicích léčby a souhlasil s léčbou. Enzalutamid byl zahájen v dávce 1600 mg dvakrát denně. Pacient je v současné době v remisi a jeho PSA klesla na 0,5 ng/ml.



RWE a metastatický karcinom prostaty: kazuistika pacienta MUDr. Jiří Navrátil, Ph.D.



Kazuistika pacienta s mCRPC léčeného Xtandi v prechemo indikaci

Úvod

Pacient 70let (77let v době dg) s diagnózou metastatického karcinomu prostaty (mCRPC) byl předtím léčen abirateronem a prednisonem. Při posledním vyšetření (PSA 10,5 ng/ml) byl pacientovi doporučeno začít s léčbou enzalutamidem. Pacient byl informován o výhodách a rizicích léčby a souhlasil s léčbou. Enzalutamid byl zahájen v dávce 1600 mg dvakrát denně. Pacient je v současné době v remisi a jeho PSA klesla na 0,5 ng/ml.

PSA 10,5 - bezprostředně po zahájení léčby Xtandi

PSA 0,5 - po 12 týdnech léčby Xtandi

PSA 0,5 - po 24 týdnech léčby Xtandi

PSA 0,5 - po 36 týdnech léčby Xtandi

PSA 0,5 - po 48 týdnech léčby Xtandi

PSA 0,5 - po 60 týdnech léčby Xtandi

PSA 0,5 - po 72 týdnech léčby Xtandi

PSA 0,5 - po 84 týdnech léčby Xtandi

PSA 0,5 - po 96 týdnech léčby Xtandi

PSA 0,5 - po 108 týdnech léčby Xtandi

PSA 0,5 - po 120 týdnech léčby Xtandi

PSA 0,5 - po 132 týdnech léčby Xtandi

PSA 0,5 - po 144 týdnech léčby Xtandi

PSA 0,5 - po 156 týdnech léčby Xtandi

PSA 0,5 - po 168 týdnech léčby Xtandi

PSA 0,5 - po 180 týdnech léčby Xtandi

